Aperon Biosystems Corp.
This article was originally published in Start Up
Executive Summary
Aperon Biosystems Corp. wants to make monitoring of nitric oxide-a reliable marker of airway inflammation--as routine for asthma patients as glucose checks are for diabetics. It is developing a low cost, noninvasive NO biosensor suitable for use at the point of care and at home for asthma self management. The company believes that regular monitoring with its device will give patients the feedback they need to better control their symptoms.
You may also be interested in...
Start-Up News October 2006
Arbios Systems and Livercyte provide assistance for the failing liver, and Aperon Biosystems takes up the asthma challenge.
Merck Suit Against Medicare: Constitutional Arguments Are Scathing, But Are They Persuasive?
A suit designed to test the limits of the protections against judicial review that are embedded in the IRA could have more traction, some legal scholars suggest.